revealed that KRAS and CDKN2A were mutated in over 90% of pancreatic cancers, while the TP53 and SMAD4 genes were mutated in 75% and 55% of the patients, respectively (8). This evidence concerns the gene CDKN2A and pancreatic neoplasm.